Incyte will work alone on developing and selling the GITR and OX40 antibody programs that it has been working on with Agenus as the partners retool their…

Johnson & Johnson has outlicensed its portfolio of hypoxia-inducible factor to Cambridge MA-based Akebia as the biotech boosts its early-stage pipeline.

VenBio has criticized the timing and terms of Immunomedics’ licensing deal with Seattle Genetics.

Seattle Genetics is to pay $250 million upfront for the rights to Immunomedics’ solid tumor asset IMMU-132.

More than 160 biotech and VC execs have signed a strongly worded letter in Nature Biotech today denouncing President Trump’s recent immigration executive order.

Renova Therapeutics has strengthened its position in heart failure by licensing rights to a peptide drug held by Janssen.

The chief of AstraZeneca, Pascal Soriot, said during the Big Pharma’s financials this morning that he wants a “science-led FDA” as President Donald Trump'…

ARCH Ventures, Versant and Cardinal Partners have come together in a $50 million Series A raise and launch for upstart Vividion.

Ophthotech has started a search for ophthalmic drugs, pipeline prospects and technologies it can rebuild its business around.